Literature DB >> 15467432

Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells.

Alessandro Sgambato1, Andrea Camerini, Beatrice Faraglia, Ernesto Pavoni, Micaela Montanari, Daniele Spada, Carmen Losasso, Andrea Brancaccio, Achille Cittadini.   

Abstract

Dystroglycan (DG) is an adhesion molecule formed by two subunits, alpha (extracellular) and beta (transmembrane) DG, which are codified by a single gene and form a continuous link from the extracellular matrix to the intracellular cytoskeleton. Reduction or loss of expression of DG has been observed in human cancer cell lines and primary tumors and has been suggested to promote tumor development and invasiveness. In this study, the human breast epithelial non-tumorigenic MCF10F and the breast cancer MCF7 cell lines were engineered to stably express an exogenous DG cDNA and the effects on the phenotype of both cell lines were evaluated. The MCF10F transfected cells displayed an increased expression of both DG subunits which was associated with inhibition of the anchorage-dependent growth, accumulation of cells in the G0/G1 phase of the cell cycle and increased adhesion to a substratum. The MCF7 transfected cells were unable to restore alpha-DG despite an increased expression of the beta-DG subunit. Anchorage-dependent and independent growth and the in vivo tumorigenicity were reduced in these derivatives that also displayed a reduced adhesion to a substratum and were shown to release alpha-DG in the culture medium. These findings confirm and extend previous evidence that transformation of mammary epithelial cells is associated with loss of their ability to retain alpha-DG on the cell membrane. Moreover, they indicate that DG is involved in cell functions other than cell adhesion to the extracellular matrix, and that its loss of function might predispose to tumor progression by compromising regulatory controls over cell growth and proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467432     DOI: 10.4161/cbt.3.10.1132

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  8 in total

1.  Dystroglycan controls signaling of multiple hormones through modulation of STAT5 activity.

Authors:  Dmitri Leonoudakis; Manisha Singh; Roozbeh Mohajer; Pouya Mohajer; Jimmie E Fata; Kevin P Campbell; John L Muschler
Journal:  J Cell Sci       Date:  2010-10-12       Impact factor: 5.285

2.  Cancer Malignancy Is Correlated with Upregulation of PCYT2-Mediated Glycerol Phosphate Modification of α-Dystroglycan.

Authors:  Fumiko Umezawa; Makoto Natsume; Shigeki Fukusada; Kazuki Nakajima; Fumiya Yamasaki; Hiroto Kawashima; Chu-Wei Kuo; Kay-Hooi Khoo; Takaya Shimura; Hirokazu Yagi; Koichi Kato
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

3.  Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer.

Authors:  Alison K Esser; Michael R Miller; Qin Huang; Melissa M Meier; Daniel Beltran-Valero de Bernabé; Christopher S Stipp; Kevin P Campbell; Charles F Lynch; Brian J Smith; Michael B Cohen; Michael D Henry
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

4.  Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer.

Authors:  G Mathew; A Mitchell; J M Down; L A Jacobs; F C Hamdy; C Eaton; D J Rosario; S S Cross; S J Winder
Journal:  Sci Rep       Date:  2013-09-30       Impact factor: 4.379

5.  Large induces functional glycans in an O-mannosylation dependent manner and targets GlcNAc terminals on alpha-dystroglycan.

Authors:  Yihong Hu; Zhi-fang Li; Xiaohua Wu; Qilong Lu
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

6.  High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer.

Authors:  Yu Liu; Shirui Huang; Mengjiao Kuang; Huiyan Wang; Qipeng Xie
Journal:  Pharmgenomics Pers Med       Date:  2021-01-18

7.  Dystroglycan and perlecan provide a basal cue required for epithelial polarity during energetic stress.

Authors:  Vincent Mirouse; Christina P Christoforou; Cornelia Fritsch; Daniel St Johnston; Robert P Ray
Journal:  Dev Cell       Date:  2009-01       Impact factor: 12.270

8.  Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients.

Authors:  Claudio Coco; Gian Franco Zannoni; Emanuele Caredda; Stefano Sioletic; Alma Boninsegna; Mario Migaldi; Gianluca Rizzo; Luca Reggiani Bonetti; Giannicola Genovese; Egidio Stigliano; Achille Cittadini; Alessandro Sgambato
Journal:  J Exp Clin Cancer Res       Date:  2012-09-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.